Cargando…
Comparative Gene Expression Profiling of Benign and Malignant Lesions Reveals Candidate Therapeutic Compounds for Leiomyosarcoma
Leiomyosarcoma (LMS) is a malignant, soft-tissue tumor for which few effective therapies exist. Previously, we showed that there are three molecular subtypes of LMS. Here, we analyzed genes differentially expressed in each of the three LMS subtypes as compared to benign leiomyomas and then used the...
Autores principales: | Edris, Badreddin, Fletcher, Jonathan A., West, Robert B., van de Rijn, Matt, Beck, Andrew H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3420093/ https://www.ncbi.nlm.nih.gov/pubmed/22919280 http://dx.doi.org/10.1155/2012/805614 |
Ejemplares similares
-
Flipping the script on macrophages in leiomyosarcoma
por: Edris, Badreddin, et al.
Publicado: (2012) -
Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling
por: Beck, Andrew H, et al.
Publicado: (2009) -
Molecular subtyping of leiomyosarcoma with 3′ end RNA sequencing
por: Guo, Xiangqian, et al.
Publicado: (2015) -
Automated Classification of Benign and Malignant Proliferative Breast Lesions
por: Radiya-Dixit, Evani, et al.
Publicado: (2017) -
Immunohistochemical expression of interleukin-17 and hormonal receptors in benign and malignant breast lesions
por: Ali, Eman Taha, et al.
Publicado: (2020)